NAD+ in aging, metabolism, and neurodegeneration

Verdin E | Science | 2015 | Evidence: strong

Plain-language summary

Published 2015 in Science, this work by Verdin E and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

Mechanistic basis for boosting NAD+ as anti-aging strategy
CD38 as major NAD+ consumer with age
Cited as rationale for NMN supplementation

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the strong end of the evidence spectrum. Strong-tier human placebo-controlled trial data carries the most weight in our editorial framework - treat findings as actionable signal, but always pair with at least one replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index